Ephedrine

# Research Output: Ephedrine

## Chemical Identity

**PubChem CID:** 9294 (api_verified) [Ref — PubChem lookup]

**IUPAC name:** (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol
*Brief seed data matches confirmed IUPAC name.*

**Molecular formula:** C₁₀H₁₅NO (api_verified via PubChem)
**Molecular weight:** 165.23 g/mol (api_verified via PubChem)
**InChIKey:** KWGRBVOPPLSCSI-WPRPVWTQSA-N (api_verified via PubChem — this is the (1R,2S)-l-ephedrine stereoisomer)
**CAS number:** 299-42-3 (conventional knowledge — not API-verified; FLAG for independent confirmation)
**SMILES:** Not returned by PubChem API call; this field remains unconfirmed and should be populated from a separate PubChem CID lookup or ChemSpider. **FLAG: SMILES absent from brief and not retrieved — generation agent should populate from PubChem CID 9294.**

**Stereochemistry:** Ephedrine has two stereocenters (C-1 and C-2) producing four stereoisomers. The pharmacologically active form found in *Ephedra sinica* is (1R,2S)-(-)-ephedrine (l-ephedrine). Its diastereomer (1S,2R)-(+)-pseudoephedrine (d-pseudoephedrine) is a distinct compound (primarily decongestant). The (1S,2S) and (1R,2R) enantiomers are largely inactive or poorly active. Feller & Malspeis (1977 [Ref 29]) showed D(-)-ephedrine is metabolized faster than L(+)-ephedrine in vitro, and Kobayashi et al. (2003 [Ref 4]) confirmed distinct pharmacological profiles between l-ephedrine and d-pseudoephedrine. The brief's systematic name (1R,2S) correctly specifies l-ephedrine.

**Physical properties:** Melting point and detailed solubility data were not retrieved via API searches. The INCHEM PIM 209 entry [Ref 31] describes a crystalline alkaloid; ephedrine hydrochloride salt is water-soluble. **FLAG: Melting point and aqueous solubility not sourced from primary literature in this research pass.**

**Brief discrepancies:**
- The brief correctly provides IUPAC name and stereodescriptor.
- Molecular formula, MW, and InChIKey were absent from the brief — now confirmed.
- PubChem CID was absent from the brief — now confirmed as 9294.
- The brief characterizes the substance as "emerging" — this is **incorrect** and should be updated. Ephedrine is a century-old compound with an extensive published literature (>1,000 peer-reviewed articles on PubMed). **FLAG: Readiness characterization "emerging" is erroneous; substance is well-established.**

---

## Pharmacology

### Mechanism of Action

Ephedrine is a mixed direct/indirect sympathomimetic amine. As reviewed by Gad et al. (2021 [Ref 1]) and described in clinical pharmacology references [Refs 30, 31]:

**Indirect (primary) mechanism:** Ephedrine inhibits the norepinephrine reuptake transporter (NET), preventing reuptake of released NE into presynaptic terminals, and displaces norepinephrine from presynaptic storage vesicles via a carrier-mediated exchange mechanism. This leads to flooding of the synaptic cleft with NE, amplifying postsynaptic adrenergic stimulation.

**Direct mechanism:** Ephedrine also acts as a direct agonist at α-1, α-2, β-1, and β-2 adrenergic receptors, though with lower potency than endogenous catecholamines. Molinoff (1984 [Ref 44]) provides the reference framework for receptor subtype pharmacology. The relative contribution of direct vs. indirect effects is debated:
- Kobayashi et al. (2003 [Ref 4]) demonstrated in anesthetized rats that the *in vivo* pressor response to l-ephedrine was entirely abolished by 6-OHDA (sympathetic terminal destruction), supporting predominantly indirect action in vivo — though approximately 50% of tissue-level responses survived 6-OHDA, suggesting meaningful direct activity at the tissue level.
- Liles et al. (2006 [Ref 5]) found ephedrine pressor responses in rats *were NOT* attenuated by NET blockade or catecholamine depletion with reserpine/α-methyl-p-tyrosine, arguing for predominantly direct α-adrenergic receptor mediation. This contrasts with amphetamine and tyramine, whose responses were abolished by the same treatments.
- **FLAG: Mechanistic debate unresolved; generation agent should present both positions without declaring a single consensus.**

**Downstream signaling:** Jia et al. (2013 [Ref 13]) demonstrated in PC12 cells that ephedrine induces thioredoxin-1 expression via a β-AR → cAMP → PKA → DARPP-32 → CREB phosphorylation pathway. Dabisch et al. (2003 [Ref 39]) showed that ephedrine-induced NO production is secondary to β-2 receptor stimulation, with NO modulating the vascular response.

**CNS mechanism:** Ephedrine crosses the blood–brain barrier. Centrally, it stimulates the release of NE and dopamine in the CNS, producing stimulant effects including alertness, appetite suppression, and mood elevation. The INCHEM PIM 209 [Ref 31] documents it as a "centrally-acting respiratory stimulant." Docherty (2008 [Ref 41]) classifies it as a monoaminomimetic agent acting on adrenergic and dopaminergic systems.

**Receptor binding affinity (Ki/EC₅₀):** No quantitative Ki or EC₅₀ values for ephedrine at individual adrenergic receptor subtypes were identified in the published literature via PubMed or OpenAlex API searches. **FLAG: Receptor binding affinity data absent from primary literature — this is a genuine data gap. The generation agent should note this absence; do not infer Ki values from structural analogy without labeling them as such.**

### Pharmacokinetics

All data below are from human studies unless otherwise noted.

| Parameter | Value | Source |
|-----------|-------|--------|
| Oral bioavailability | ~88% | StatPearls [Ref 30] |
| Tmax (oral) | ~1–1.8 hours | INCHEM [Ref 31]; StatPearls [Ref 30] |
| Half-life (plasma) | 3–6 hours (pH-dependent) | INCHEM [Ref 31] |
| Volume of distribution | ~3 L/kg (215.6 L) | INCHEM [Ref 31]; StatPearls [Ref 30] |
| Protein binding | ~24–29% (5–10% albumin) | DrugBank (web-retrieved) |
| Renal excretion unchanged | 53–74% of administered dose | Sever et al. 1975 [Ref 28] |
| Total urinary recovery (48h) | 97% | Sever et al. 1975 [Ref 28] |
| Placental transfer | Yes | StatPearls [Ref 30] |

**Absorption:** Ephedrine is rapidly and essentially completely absorbed from the GI tract. A 24 mg oral dose yields mean peak plasma concentration of ~0.10 mg/L [Ref 31].

**Metabolism:** Minimal first-pass hepatic metabolism. No significant CYP enzyme involvement documented in the literature. Sever et al. (1975 [Ref 28]) characterized three urinary metabolic pathways in humans:
1. **Unchanged ephedrine:** 53–74% (major fraction)
2. **N-demethylation → norephedrine:** 8–20%
3. **Oxidative deamination → benzoic acid + 1,2-dihydroxy-1-phenylpropane (free and conjugated):** 4–13%

Importantly, no phenolic metabolites are detected, distinguishing ephedrine metabolism from catecholamines. The primary metabolite norephedrine retains some adrenergic activity. Feller & Malspeis (1977 [Ref 29]) confirmed N-demethylation and oxidative deamination as the major pathways in rabbits, with stereoisomeric differences (D(-)-ephedrine metabolized ~3× faster than L(+) for benzoic acid formation).

**Urinary pH dependence:** Elimination is markedly pH-dependent. INCHEM [Ref 31] and Brater et al. (1980 [Ref 37]) document that acidic urine greatly enhances renal clearance, while alkaline urine prolongs half-life dramatically (data from pseudoephedrine, the structural analog, showed half-life extending from ~2 h to ~21 h with alkalinization). This pharmacokinetic property has clinical implications for urine acidification in overdose management.

**Onset of clinical effect (oral):** Pickup et al. (1976 [Ref 6]) measured plasma ephedrine levels in asthmatics after a 22 mg oral dose, with pharmacokinetic profiling consistent with Tmax ~1 h. The brief's onset range of 20–90 minutes is plausible but the lower bound of 20 min is slightly fast given documented Tmax data; 30–90 min better reflects the published literature. **FLAG: Onset lower bound (20 min) may be slightly early for oral route; literature better supports 30–90 min. Propose editorial review of onset parameter.**

---

## History

Ephedrine originates from *Ephedra sinica* (ma huang), a plant used in Traditional Chinese Medicine for several thousand years. Ma huang was first recorded in the *Sheng Nong's Herbal Classic* (神農本草經, ~2nd century BCE) as a treatment for respiratory ailments (Zheng et al. 2023 [Ref 16]).

Lee MR (2011 [Ref 27]) provides a comprehensive historical narrative:

- **1885:** Japanese organic chemist Nagai Nagayoshi (1844–1929) isolated and characterized ephedrine as the pure alkaloid from *Ephedra sinica*, applying Western analytical chemistry to traditional herbal medicine at Tokyo Imperial University.
- **1885–1920s:** The compound was largely ignored in Western pharmacology.
- **Early 1920s:** Chinese-American pharmacologist Ko Kuei Chen (K.K. Chen) and Carl F. Schmidt rediscovered ephedrine and established its pharmacological profile. Their work demonstrated that ephedrine's actions could be classified as separate alpha and beta adrenergic effects — a defining moment in the history of autonomic pharmacology.
- **1920s–1950s:** Ephedrine became a highly popular and effective treatment for asthma, distinguishing itself from adrenaline (then the standard) by being orally bioavailable. It was also used for bronchitis, nasal congestion, narcolepsy, and hypotension. Wennergren et al. (2025 [Ref 32]) document its use in respiratory medicine from ancient times through the early modern era.
- **1950s–1960s:** Ephedrine's use in asthma declined as more selective β-2 agonists (salbutamol introduced 1969) replaced it.
- **1970s–1990s:** Ephedrine moved from mainstream medicine into dietary supplements and athletic performance enhancement.
- **2000:** Haller & Benowitz published landmark NEJM review of 140 FDA adverse event reports [Ref 2], demonstrating 10 deaths and 13 cases of permanent disability associated with ephedra-containing supplements.
- **2003:** Shekelle et al. published JAMA meta-analysis [Ref 3] confirming modest short-term weight loss but significant psychiatric, autonomic, and cardiovascular adverse event risk.
- **April 12, 2004:** FDA final rule [Refs 14, 26] banned dietary supplements containing ephedrine alkaloids under DSHEA as presenting an "unreasonable risk of illness or injury."
- **2005:** Combat Methamphetamine Epidemic Act classified ephedrine as a List I chemical (methamphetamine precursor), imposing behind-counter sales restrictions, ID requirements, and purchase limits.

---

## Subjective Effects

Human controlled study data are limited. Chait LD (1994 [Ref 40]) provides the most direct characterization:

**Study design:** 27 adults (18F, 9M), no drug dependence history. Single oral dose selected to produce moderate response (range 37.5–75 mg). Discrete-trial choice procedure.

**Findings:**
- Ephedrine chosen on 17% of available occasions (low reinforcing potential)
- Increased ratings of "high" and scores on MBG ("euphoria") scale of Addiction Research Center Inventory
- Increased scores on mood scales reflecting CNS stimulation and anxiety
- No effect on drug "liking" ratings overall
- Males chose ephedrine more frequently and showed more positive mood response
- Choice associated with lower baseline anxiety, current cannabis use, lower harm-avoidance personality scores

**From clinical/toxicological literature:** The INCHEM entry [Ref 31] documents subjective and behavioral effects across the dose spectrum:
- *Stimulant effects:* wakefulness, alertness, increased motor activity, respiratory stimulation, appetite suppression
- *Cardiovascular:* palpitations, tachycardia (subjectively experienced as "racing heart")
- *CNS stimulation:* anxiety, agitation, tremor
- *At higher doses/chronic use:* mental confusion, hallucinations, mania, paranoid psychosis, seizures

**Effects taxonomy notes (cross-referenced with brief):**
The effects taxonomy in the brief (stimulation, wakefulness, appetite suppression, anxiety, motivation enhancement, etc.) is consistent with the published literature. The following taxonomy entries have direct support:
- *Stimulation, Wakefulness, Appetite suppression* — confirmed [Refs 40, 31, 30]
- *Anxiety* — confirmed as common dose-dependent effect [Refs 40, 31]
- *Vasoconstriction, Abnormal heartbeat* — confirmed via mechanism [Refs 2, 31]
- *Pupil dilation* — confirmed (adrenergic mydriasis) [Ref 31]
- *Respiratory stimulation* — confirmed [Ref 31]
- *Excessive sweating* — consistent with sympathomimetic stimulation; documented in case reports
- *Tactile euphoria, Empathy enhancement, Sexual arousal enhancement* — not confirmed in published controlled studies. These effects appear in user-report context. **FLAG: No published controlled-study data for these specific effects. Label as user-report only in prose.**
- *Ego inflation* — not documented in clinical or controlled literature. **FLAG: Entirely user-report; should be labeled accordingly.**
- *Music enhancement, Visual acuity enhancement* — not documented in peer-reviewed literature. **FLAG: Not confirmed in published data.**
- *Double vision* — not documented as expected effect; possible at toxic doses from CNS overstimulation. **FLAG: Verify in effects taxonomy context.**
- *Time alteration* — consistent with general stimulant class; not directly documented in ephedrine-specific studies.
- *Bruxism* — not directly documented for ephedrine specifically; consistent with stimulant class. **FLAG: Class inference only.**
- *Emotional suppression, Irritability* — consistent with stimulant profile; not directly confirmed in ephedrine-specific controlled studies.

---

## Safety & Toxicity

### Human Toxicity

**Documented fatal blood concentrations** (INCHEM [Ref 31]):
- 3.49, 7.85, and 20.5 mg/L in three documented fatalities
- Survival documented at 23 mg/L
- These concentrations provide context but do not define a precise LD threshold in humans

**Therapeutic concentrations:** A 24 mg oral dose produces mean peak plasma ~0.10 mg/L; clinical dosing produces concentrations well below the lowest reported fatal level [Ref 31].

**Animal LD₅₀:** No animal LD₅₀ data were identified in accessible published sources via API searches or INCHEM. **FLAG: Animal LD₅₀ not available in this research pass. Generation agent should note absence; do not fabricate values.**

**Adverse event profile (Haller & Benowitz 2000 [Ref 2]):** Analysis of 140 FDA adverse event reports:
- 47% cardiovascular symptoms
- 18% CNS symptoms
- Hypertension most common (17 reports)
- Palpitations/tachycardia (13 reports)
- Stroke (10 reports)
- Seizures (7 reports)
- 10 deaths, 13 permanent disabilities (26% of probable/possible cases)

**Systematic evidence (Shekelle et al. 2003 [Ref 3]):** Meta-analysis of 50 trials showed 2.2–3.6-fold increase in odds of psychiatric, autonomic, or gastrointestinal symptoms and heart palpitations versus placebo.

**Large epidemiological study (Hallas et al. 2008 [Ref 8]):** Registry-based case-crossover study of 257,364 users of prescribed ephedrine/caffeine (Denmark) found no significantly increased risk of death, MI, or stroke (adjusted OR 0.95, 95% CI 0.79–1.16). This contrasts with the FDA case series and likely reflects the difference between prescribed therapeutic use and uncontrolled supplement use.

### Cardiovascular Toxicity

- **Acute MI:** Kranjec et al. (2009 [Ref 9]) case report: intracoronary thrombus in LAD in a young athlete with ephedrine abuse.
- **Cardiomyopathy:** Clark & Schofield (2005 [Ref 11]) reported dilated cardiomyopathy with combined ephedra/GHB/anabolic steroid use. Martinez-Quintana et al. (2010 [Ref 19]) documented biventricular dysfunction and myocardial necrosis from chronic ephedrine abuse; partial LV recovery after 5 years' abstinence.
- **Arrhythmia risk:** Significantly elevated with concurrent use of halogenated anesthetics, cardiac glycosides, quinidine, TCAs, ergot alkaloids [Ref 31].

### CNS/Psychiatric Toxicity

- Psychosis: documented in multiple case reports and series [Refs 21, 22, 23]
- Mania: documented [Ref 21]
- Substance-induced psychotic disorder in 67% of cough mixture abusers (Tang et al. 2012 [Ref 23])
- Seizures: reported in FDA adverse event series [Ref 2]

### Metabolic Effects

- Hyperglycemia (beta-adrenergic stimulation of glycogenolysis)
- Hypokalemia (intracellular potassium shift via beta-adrenergic stimulation)
- Metabolic acidosis (in severe toxicity) [Ref 31]

### Special Populations

**Pregnancy:** Ephedrine crosses the placental barrier [Ref 30]. In obstetric anesthesia, ephedrine use for post-spinal hypotension is associated with lower neonatal umbilical artery pH values versus phenylephrine (Lee et al. 2002 [Ref 15]; Lee et al. 2017 [Ref 36]). The mechanism is thought to involve beta-adrenergic stimulation of fetal glucose and lactate metabolism.

---

## Harm Reduction

Based on published literature:

1. **Avoid concurrent MAOI use:** Contraindicated within 14 days of MAOI therapy; risk of life-threatening hypertensive crisis [Refs 30, 31].
2. **Avoid concurrent stimulants:** Ephedrine/caffeine combination significantly increases cardiovascular and CNS adverse event risk [Ref 7]; ephedrine/caffeine is 2.2–3.6× more likely to cause adverse events than either alone [Ref 3].
3. **Cardiovascular pre-screening:** Use is contraindicated in known ischemic heart disease, acute hypertension, tachycardia, aortic stenosis [Ref 30].
4. **Urinary acidification in overdose:** May be considered to enhance renal elimination in acute toxicity; however, high volume of distribution (3 L/kg) makes hemodialysis ineffective [Ref 31].
5. **Avoid volatile halogenated anesthetics:** Arrhythmia risk with cyclopropane and halothane [Ref 31].
6. **Blood pressure monitoring:** Required during clinical administration; severe hypertension managed with phentolamine 5 mg IV or 100 mg oral [Ref 31].
7. **Emergency treatment of convulsions:** IV benzodiazepines (diazepam); severe tachyarrhythmias may require IV esmolol [Ref 31].
8. **Detection (sports context):** In-competition urinary threshold is 10 mcg/mL [Ref 41]. Testing for ephedrine via immunoassay or LC-MS/MS.

**Contraindications (from literature [Refs 30, 31]):**
- Concurrent or recent (< 14 days) MAOI therapy
- Acute hypertension or tachyarrhythmia
- Ischemic heart disease or recent MI
- Aortic stenosis
- Urinary retention / prostatic hyperplasia
- Pheochromocytoma (adrenal catecholamine excess)

---

## Tolerance & Dependence

**Tachyphylaxis:** Rapid tolerance (tachyphylaxis) develops with repeated doses, documented in both animal and human literature. Liles et al. (2006 [Ref 5]) demonstrated sequential injection tachyphylaxis in rats; notably, ephedrine tachyphylaxis also attenuated subsequent responses to alpha-receptor agonists — suggesting receptor-level downregulation as a component.

**Tolerance mechanism:** Pickup et al. (1976 [Ref 6]) showed in asthmatics that kinetic parameters do not change with chronic dosing — confirming tolerance is pharmacodynamic, not pharmacokinetic. Sever et al. (1975 [Ref 28]) noted absence of phenolic metabolites, ruling out an inhibitory metabolite as the tolerance mechanism. Most likely mechanism: depletion of NE from presynaptic terminals (for indirect effects) plus receptor downregulation (for direct effects).

**Dependence liability:** Chait (1994 [Ref 40]) found low reinforcing potential (17% choice rate) in non-dependent adults, suggesting moderate abuse liability. Miller (2005 [Ref 20]) published case documentation of addiction to ephedra preparations. Cough mixture abuse data (Tang et al. 2012 [Ref 23]) demonstrate ephedrine-containing formulations can produce substance-use disorder in chronic users.

**Withdrawal:** Not well characterized in peer-reviewed literature. There is no specific ephedrine withdrawal syndrome described in controlled studies. **FLAG: Absence of published data on withdrawal syndrome; generation agent should note this gap explicitly.**

**Cross-dependence with opiates:** Dambisya et al. (1991 [Ref 43]) showed in mice that chronic ephedrine pretreatment enhanced opiate tolerance and suppressed withdrawal signs — suggesting shared mechanisms, but this is animal data only.

---

## Drug Interactions

All interactions below are from published clinical pharmacology sources [Refs 30, 31] unless otherwise noted:

| Drug/Class | Mechanism | Clinical Consequence | Severity |
|---|---|---|---|
| MAOIs (tranylcypromine, phenelzine, selegiline) | Blocked MAO → excessive NE accumulation | Life-threatening hypertensive crisis, hyperpyrexia | Contraindicated (<14 days) |
| Halogenated anesthetics (halothane, cyclopropane) | Sensitize myocardium to catecholamines | Severe ventricular arrhythmias | Contraindicated |
| Cardiac glycosides (digoxin) | Additive proarrhythmic effects | Increased arrhythmia risk | Major |
| Tricyclic antidepressants | Potentiate NE-mediated pressor response | Severe hypertension, arrhythmia | Major |
| Ergot alkaloids, oxytocin | Additive vasoconstriction | Severe hypertension | Major |
| Paroxetine (SSRIs) | Serotonin syndrome mechanism | Serotonin syndrome risk [Ref 31] | Major |
| Quinidine | Additive proarrhythmic effects | Increased arrhythmia risk | Moderate |
| Theophylline | Additive CNS stimulation | Increased nervousness, insomnia | Moderate |
| Alpha/beta-blockers, reserpine | Pharmacodynamic antagonism | Reduced vasopressor efficacy | Moderate |
| Rocuronium | Enhanced circulatory delivery → faster distribution to NMJ | Shortened onset of neuromuscular blockade [Ref 30] | Moderate |
| Caffeine | Pharmacodynamic synergy | Enhanced cardiovascular and CNS effects; 2.2–3.6× adverse events [Refs 3, 7] | Moderate |

---

## Legal Status

| Jurisdiction | Status | Details |
|---|---|---|
| United States | List I Chemical; banned from dietary supplements | Not CSA-scheduled. Dietary supplement ban: April 12, 2004 (FDA final rule). Combat Methamphetamine Epidemic Act 2005: sold behind-the-counter with ID, logbook, monthly purchase limits. Some states have enacted additional scheduling. |
| Australia | Schedule 4 (Prescription Only) | TGA classification; prescription required for all formulations; possession without prescription illegal. |
| Canada | Class A Precursor | Controlled Drugs and Substances Act. Sold OTC as natural health product (NHP) max 8 mg/tablet, 400 mg/package. |
| United Kingdom | Regulated under Medicines Act | Available in limited OTC preparations with quantity restrictions; controlled as methamphetamine precursor. |
| WADA (sports) | Prohibited in-competition | Urinary threshold 10 mcg/mL [Ref 41]. Banned since pre-2003; continuously listed on WADA Prohibited List. |
| European Union | Generally prescription-only | EU drug precursor regulations apply; Schedule III chemical precursor in most member states. **FLAG: EU specific legal status not confirmed from primary sources in this research pass — generation agent should note uncertainty.** |

---

## Clinical Trials

**Active/Recent Trials (from ClinicalTrials.gov search):**

1. **NCT05497700** — *Comparative Efficacy of Ephedrine Versus Norepinephrine to Correct Anesthesia Induction Related Hypotension* | Phase 3 | Status: Unknown | Sponsor: Brugmann University Hospital | Condition: Hypotension on Induction

2. **NCT06668337** — *Ephedrine Doses to Prevent Maternal Hypotension After Spinal Anesthesia in Cesarean Section* | Phase 4 | Status: Completed | Sponsor: B.P. Koirala Institute of Health Sciences, Nepal | Condition: Hypotension after spinal anesthesia; hypotension during cesarean delivery

**Active systematic review landscape (2025–2026):** The current research landscape for ephedrine is dominated by comparative effectiveness reviews in obstetric anesthesia, consistently showing norepinephrine > phenylephrine > ephedrine for prevention and treatment of post-spinal hypotension [Refs 33, 34, 35, 36]. No active or registered trials for ephedrine in weight loss or athletic performance were found, consistent with the 2004 FDA ban.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical Gaps (Safety-Relevant)

1. **Receptor binding affinity (Ki/EC₅₀):** No quantitative binding affinity data for ephedrine at individual adrenergic receptor subtypes (α₁, α₂, β₁, β₂) found in accessible literature. Generation agent should note absence; do not infer values. **SAFETY-CRITICAL FLAG.**

2. **Animal LD₅₀:** Not found in accessible published sources. INCHEM did not provide LD₅₀ values. Human fatal concentrations documented (3.49–20.5 mg/L) but therapeutic index is not formally established. **SAFETY-CRITICAL FLAG.**

3. **Onset duration lower bound:** Brief states onset 20–90 minutes for oral route. Published Tmax data (1–1.8 h) better supports onset of 30–90 min. 20 min may be too fast for oral route. **Propose revision to 30–90 minutes; flag for editorial review.**

### Data Quality Flags

4. **"Emerging" characterization:** Brief characterizes ephedrine as "emerging" — this is incorrect. Ephedrine is a well-established compound isolated in 1885 with extensive published literature. Should be updated to "well-studied" or equivalent.

5. **SMILES string absent:** Not returned by PubChem API; generation agent should populate from PubChem CID 9294 directly.

6. **CAS number 299-42-3:** Common knowledge, not API-verified in this research pass.

7. **EU legal status:** Not confirmed from primary sources. Stated as "generally prescription-only" based on class inference and precursor regulations. Should be verified independently.

8. **Specific subjective effects (empathy enhancement, sexual arousal enhancement, ego inflation, music enhancement, visual acuity enhancement, double vision):** No published controlled-study data found. These appear to be user-report data. Should be labeled as user-report only in prose; do not present as literature-confirmed.

9. **Withdrawal syndrome:** Not characterized in published peer-reviewed literature. Generation agent should note absence.

10. **Cross-tolerance profile:** Minimal published data; Dambisya 1991 [Ref 43] provides only animal (mouse) data on opiate cross-effects.

11. **Toxicity note in brief:** Brief states "Inferred from pharmacological class — not sourced from literature. Review recommended." — Confirmed: the review above provides sourced toxicity data from Refs 2, 3, 9, 11, 19, 31. The toxicity characterization as "moderate" (both acute and chronic) is conservative but defensible given the documented fatalities and serious cardiovascular events.

12. **Dose sensitivity field:** Blank in brief. Dose validation from literature: therapeutic oral dose 25 mg q4h (up to 150 mg/day); weight loss studies used 20 mg TID (Astrup 1992 [Ref 17]); subjective effects study used 37.5–75 mg (Chait 1994 [Ref 40]). Seed dose ranges are plausible but generated without primary sources — generation agent should note these as editorially reviewed, not independently published dose characterizations for recreational use.